Serotonin 3 receptor antagonists - Pipeline Insight, 2022

Serotonin 3 receptor antagonists - Pipeline Insight, 2022

  • January 2022 •
  • 60 pages •
  • Report ID: 6068399 •
  • Format: PDF
“Serotonin 3 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Serotonin 3 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Serotonin 3 Receptor Antagonists Understanding

Serotonin 3 Receptor Antagonists: Overview
Serotonin receptor (5-HT3AR) is the most common therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of irritable bowel syndrome. Setrons, a class of competitive antagonists, cause functional inhibition of 5-HT3AR in the gastrointestinal tract and brainstem, acting as effective anti-emetic agents.

Function – The 5-HT3 receptors, like nicotinic acetylcholine (nACh), GABAA/C, and glycine receptors, are members of the Cys-loop family of pentameric ligand-gated ion channels. They play important roles in fast neurotransmission in the central and peripheral nervous systems. 5-HT3 receptors are located primarily in the chemoreceptor trigger zone in the area postrema and in the gastrointestinal (GI) tract, where they have roles in regulating gut motility and the emesis reflex.

Serotonin 3 Receptor Antagonists- Serotonin (5-HT3) receptor antagonists are commonly used to decrease nausea and vomiting for surgery patients. Selective serotonin receptor (5-HT3) antagonists block serotonin both peripherally, on gastrointestinal (GI) vagal nerve terminals, and centrally in the chemoreceptor trigger zone. This blockade results in powerful antiemetic effects.

Serotonin 3 Receptor Antagonists Emerging Drugs Chapters
This segment of the Serotonin 3 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Serotonin 3 Receptor Antagonists Emerging Drugs
• AD04 (ondansetron): Adial Pharmaceuticals
Ondansetron is a 5-HT3 receptor antagonist which is being developed by Adial Pharmaceuticals. Preclinical and pharmacobehavioral studies suggest that blockade of serotonin-3 receptors will influence the dopamine reward system activated by alcohol, decreasing dopamine release and attenuating craving for alcohol. The drug is currently in phase III stage of development for the treatment of Alcohol addiction.

• DS-001: DAS Therapeutics
DAS-001 is a proposed fixed-dose combination tablet that combines the gold standard first-line treatment, pyridostigmine, with an antagonist of the gastrointestinal side effects of pyridostigmine. A successful Phase 1 study was completed in healthy volunteers and the company had begun Phase 2 clinical trial enrollment.
Further product details are provided in the report……..

Serotonin 3 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Serotonin 3 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Serotonin 3 Receptor Antagonists
There are approx. 10+ key companies which are developing the Serotonin 3 Receptor Antagonists. The companies which have their Serotonin 3 Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include ADial Pharmaceuticals.
• Phases
This report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Serotonin 3 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Serotonin 3 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin 3 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin 3 Receptor Antagonists drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin 3 Receptor Antagonists R&D.
• The therapies under development are focused on novel approaches for Serotonin 3 Receptor Antagonists.

Serotonin 3 Receptor Antagonists Report Insights
• Serotonin 3 Receptor Antagonists Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Serotonin 3 Receptor Antagonists Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Serotonin 3 Receptor Antagonists drugs?
• How many Serotonin 3 Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Serotonin 3 Receptor Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Serotonin 3 Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Serotonin 3 Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?